Background Phase II randomized controlled trials (RCTs) on factor (F) XI inhibitors have
shown promising results but they were burdened by low statistical power for clinical …

Significant advancements have shaped the landscape of anticoagulant therapy in the past
two decades, including the introduction of direct oral anticoagulants (DOACs), characterized …

Background Thrombus formation is the result of the disruption of the complex homeostatic
system involving platelets, coagulation factors, inflammatory elements, cytokines, and the …

Background Among patients treated with a novel oral anticoagulant (NOAC) undergoing
percutaneous coronary intervention (PCI), combination therapy with clopidogrel (ie, known …

Direct oral anticoagulants (DOACs)(ie, dabigatran, rivaroxaban, apixaban, and edoxaban)
have now largely replaced vitamin K antagonists (VKAs) for the treatment and prevention of …

Background The presence of residual cardiovascular risk is an important cause of
cardiovascular events. Despite the significant advances in our understanding of residual …

Upon completion of the thematic series on “Novel and Potential Markers for Prediction of
Outcome in Patients with Chronic and Acute Coronary Heart Disease”, comprising a total of …

Pan-vascular disease, a term encompassing a range of conditions primarily characterized
by atherosclerosis within the vascular system, presents a significant challenge to our …

A strategy of oral anticoagulants (OAC) in addition to single or dual antiplatelet therapy,
known as dual-pathway inhibition (DPI), has shown to reduce thrombotic events in patients …